Network for Excellence in Neuroscience Clinical Trials Center at The Ohio State University

俄亥俄州立大学神经科学卓越临床试验中心是最早的NeuroNEXT中心之一，并对该网络保持着强烈的承诺和热情。我们的中心由俄亥俄州立大学韦克斯纳医学中心(OSUWMC)和全国儿童医院(NCH)的内科研究人员组成，为NeuroNEXT的成功做出了巨大贡献，也是少数几个被选中参加所有八项资助研究的中心之一。成为NeuroNEXT的会员对俄亥俄州立大学神经病学产生了重大影响，为我们的患者提供了重要的参与研究的新机会，并促进了项目文化的转变，转向更多由研究人员发起的由NIH资助的临床研究。俄亥俄州立大学神经病学在多个重要的绩效指标方面处于领先地位，包括随机或确认受试者的数量(顶级站点)、开始新试验的效率(第三快)和数据准确性(第四)。我们在成功的基础上维护和优化我们的NeuroNEXT基础设施。领导层将简化为由四名关键人员组成。我们的NeuroNEXT中心内的协作将在现场领导层和一大批经验丰富、可靠且积极的潜在合作研究人员之间进行协调，这些合作研究人员横跨临床神经科学的所有领域。我们将在使我们成为NeuroNEXT最成功的招聘网站的创新、多方面的招聘和外展方法的基础上再接再厉。我们将通过创建研究协调员表彰计划来扩大我们对研究协调员宣传的重视。在每项研究过程中，我们将加强NeuroNEXT领导层和每个积极研究团队之间的监督。我们大力支持NeuroNEXT下一个周期对职业发展的重视。我们将实施NeuroNEXT临床试验奖学金，以扩大经验丰富的临床研究人员和研究人员的队伍，他们将成为多中心临床研究试验的领导者。俄亥俄州立大学的NeuroNEXT研究员将被要求在两年的团结期结束前向NeuroNEXT网络提交一份临床研究提案。明确的期望和里程碑要求将在详细说明课程和培训时间表的个人发展计划(IDP)中制定和正式确定。将成立一个强制性指导委员会，由俄亥俄州立大学神经研究所提供的NeuroNEXT领导层、一名主要导师和一名生物统计学家组成，以帮助支持伙伴项目的发展。指导委员会将每季度更新和审查IDP，课程将与OSUWMC和NINDS现有的培训基础设施相联系。在第二年，将正式确定下一阶段受保护培训时间的“五年计划”，该计划将与现有的学前教育和知识教育奖励机会相结合。因此，NeuroNEXT研究员将很有可能保持他们的势头，并成功过渡到一个独立的、有资金支持的和富有成效的临床试验人员。

The Network of Excellence in Neuroscience Clinical Trial Center at The Ohio State University is one of the original NeuroNEXT centers and maintains a strong commitment and enthusiasm for the network. Our center, comprised of physician investigators at The Ohio State University Wexner Medical Center (OSUWMC) and Nationwide Children's Hospital (NCH), has contributed substantially to the success of NeuroNEXT and is one of the few centers selected to enroll in all eight funded studies. Membership in NeuroNEXT has had a meaningful impact for Ohio State Neurology by providing our patients with important new opportunities for research participation and contributing to a programmatic cultural shift towards more investigator-initiated NIH- funded clinical studies. Ohio State Neurology was a leader in multiple important performance metrics, including the number of randomized or confirmed subjects (top site), efficiency in starting new trails (third fastest) and data accuracy (fourth). We build upon our success to maintain and optimize our NeuroNEXT infrastructure. The leadership administration will be simplified to consist of four key personnel. Collaboration within the our NeuroNEXT Center will be coordinated between site leadership and a large pool of experienced, reliable and motivated potential co-investigators that span all areas of clinical neuroscience. We will build upon the innovative, multifaceted approach to recruitment and outreach that has made us the most successful recruiting site in NeuroNEXT. We will extend our emphasis on research coordinator advocacy with the creation of a Research Coordinator Recognition Program. We will increase the oversight between the NeuroNEXT leadership and each active study team during the course of each study. We energetically support the emphasis on career development in the next cycle of NeuroNEXT. We will implement the NeuroNEXT Clinical Trial Fellowship to expand the pool of experienced clinical investigators and research staff who will be leaders of multicenter clinical research trials. The NeuroNEXT Fellow at OSU will be required to submit a clinical study proposal to the NeuroNEXT Network by the end of the two-year Fellowship period. Clear expectations and milestone requirements will be made and formalized in an Individual Development Plan (IDP) detailing curriculum and training timelines. A mandatory mentorship committee will be formed consisting of NeuroNEXT leadership, a primary mentor and a biostatistician provided by the OSU Neurological Research Institute to help support the development of Fellow projects. The IDP will be updated and reviewed quarterly by a mentorship committee and curriculum will link to existing training infrastructure at OSUWMC and NINDS. In the second year, a “Five Year Plan” for the next phase of protected training time will be formalized that is integrated with existing pre-K and K award opportunities. Thus, NeuroNEXT Fellows will have a high likelihood to sustain their momentum and successfully transition to an independent, funded and productive clinical trialist.